In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.
hivresourcetracking.org
The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.
Much Accomplished, Much to Do: A Conversation Looking Back & Looking Ahead with Tony Fauci
November 28, 2022
AVAC Executive Director Mitchell Warren spoke with NIAID Director, Anthony Fauci to discuss all that’s been accomplished in the HIV and COVID-19 responses over the years, what’s ahead, and what the future looks like for NIAID, for Dr. Fauci and for pandemic preparedness.
Efficacy is Not the Only HIV Prevention Attribute that Matters – Lessons from Contraception
The Research Says Yes, YES, YES – Just Like That
Faster, Smarter and More Equitable – Accelerating Roll Out and Uptake of CAB for PrEP
Monday, August 8, 2022
As we begin rolling out injectable cabotegravir (CAB) as PrEP, what lessons have we learned from the first 10 years of oral PrEP implementation? How can we do better with a new PrEP intervention that offers new opportunities and distinct challenges? Learn more in this Choice Agenda webinar.
Featuring Rachel Baggaley, Caroline Carnevale, Monica Gandhi and Mitchell Warren
CROI and Community and YOU – Preparing for CROI 2023
Doxycycline for STI Prevention: Evidence and Current Research
Friday, October 7, 2022
Very high STI prevalence is being observed globally. Doxycycline post-exposure prophylaxis (dPEP) has been proposed as an STI prevention strategy to reduce chlamydia, syphilis, and possibly gonorrhea, and trials are ongoing among cisgender gay and bisexual men as well as African cisgender women. Learn about the latest scientific data and more during this Choice Agenda webinar.
Featuring Dr. Connie Celum, Jennifer Mahn, Dr. Victor Omollo, Rodney Perkins and Dr. Jenell Stewart
More than Vessels: Pregnant people deserve inclusion in HIV prevention clinical and implementation research
Wednesday, December 14, 2022
During this webinar, panelists explored the need for Pregnant and Lactating Populations (PLP) to be included HIV prevention clinical and implementation research
Speakers included Dr. Elaine Abrams, Raniyah Copeland, Dr. Lisa Noguchi and Dr. Lynda Stranix-Chibanda. The discussion was moderated by Dr. Dvora Joseph Davey.
Status Updates on Ongoing and Planned HIV Prevention Trials
The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
Ongoing Studies for the Treatment and Prevention of the COVID-19 Virus
This table is a work in progress, as this is an incredibly dynamic landscape. Over the past month, the scientific community has accelerated development of COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of resources available to track these developments.
In addition, a collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration and Treatment Action Group offers concise overviews and analyses of key research areas.